In 2007 the CSO and Founder of Quantumcyte™, John Butler's wife was diagnosed with late stage metastatic carcinoid cancer, a rare incurable untreatable disease at that time.
Since then John has devoted his life to the development of a technology that would deliver a set of capabilities to study cancer in a very unique way. Armed with a knack for developing products that answer complex biological questions, an amazing network of scientists, engineers, computational biologists, business development professionals, and a supportive network of investors and scientific advisors, John teamed up with Quantumcyte’s CEO/CTO and Founder, Dr. Bidhan Chaudhuri.
Together John and Bidhan embarked on a journey to develop a product that would enable cancer research and clinical communities to study and diagnose cancer a very unique way. The result of their efforts is the creation of a product called QCPRECISE™. QCPRECISE™ represents a cutting edge fusion of AI based digital pathology and molecular analysis. This innovative workflow not only generates unique translational data but also introduces novel clinical workflows that tackle the challenge of cancer’s heterogeneity. It empowers us to develop groundbreaking clinical tests for cancer, metastatic disease, and other solid tissue diseases.
Throughout this journey, the Quantumcyte™ team has cultivated strong relationships with major clinical labs in hospitals, translation research institutions in academia, and major Pharma companies all excited to use the QCPRECISE!™ system to advance their critical work.
